Charles River Laboratories International, Inc. (CRL)

CIK 0001100682 · Healthcare · Diagnostics and Research

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q2-2026 8-K (2026-08-05) · 99.1
Q1-2026 8-K (2026-05-07) · 99.1
Latest FY-2025 8-K (2026-02-18) · 99.1  |  8-K (2026-01-13)
Q3-2025 8-K (2025-11-05) · 99.1
Q2-2025 8-K (2025-08-06) · 99.1
Q1-2025 8-K (2025-05-07) · 99.1
FY-2024 8-K (2025-02-19) · 99.1
Q3-2024 8-K (2024-11-06) · 99.1
Q2-2024 8-K (2024-08-07) · 99.1
Q1-2024 8-K (2024-05-09)
FY-2023 8-K (2024-02-14) · 99.1
Q3-2023 8-K (2023-11-08) · 99.1

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover Page
Audit Information
—
Statements
Consolidated Statements of Income
Consolidated Statements of Income (loss)
Consolidated Statements of Comprehensive Income
Consolidated Statements of Comprehensive Income (loss)
Consolidated Balance Sheets
Consolidated Balance Sheets (P)
Consolidated Statements of Cash Flows
Consolidated Statements of Changes In Equity and Redeemable Noncontrolling Interests
Consolidated Statements of Changes In Equity
Notes
Acquisitions
—
Acquisitions and Divestitures
Award Timing Disclosure
—
Basis of Presentation
—
Commitments and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Debt and Other Financing Arrangements
Description of Business and Summary of Significant Accounting Policies
—
Employee Benefit Plans
—
Equity and Noncontrolling Interests
Fair Value
Goodwill and Intangible Assets
Income Taxes
Insider Trading Arrangements
Insider Trading Policies and Procedures
—
Inventory
Leases
—
Pay Vs Performance Disclosure
Property, Plant and Equipment, Net
Restructuring and Asset Impairments
Revenue From Contracts With Customers
Segment and Geographic Information
Stock-based Compensation
—
Supplemental Balance Sheet Information
—
Supplemental Cash Flow Information
Venture Capital and Strategic Equity Investments